Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has initiated enrollment in the post-market CONNECT-AV study for the WavelinQ™ EndoAVF System, aimed at evaluating its effectiveness in hemodialysis access. This prospective study will track 280 patients over 24 months, measuring primary endpoints such as successful cannulation rates and device safety. The global hemodialysis patient population relies heavily on AV fistulas, making this research critical. BD's innovative approach provides a minimally invasive option compared to traditional surgical methods, enhancing patient care.
BD (Becton, Dickinson and Company) has appointed Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021. McCombs, with over 20 years of experience in medical device innovation, previously led R&D for BD's Medical Segment. Her role will focus on driving the company's innovation strategy and managing R&D efforts. Additionally, BD has established a new Scientific Advisory Board to enhance its innovation pipeline, with John DeFord as co-chair following his retirement on May 28, 2021.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to shareholders on record as of June 9, 2021. This indicates an annual dividend rate of $3.32 per share, reflecting the company's commitment to returning value to its investors.
On April 27, 2021, CerTest Biotec and BD (Becton, Dickinson and Company) announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit can now detect COVID-19 using saliva specimens on the BD MAX™ Molecular Diagnostic System. This addition enhances testing flexibility, allowing for nasopharyngeal, oropharyngeal, and saliva sample collection. The kit is CE marked and capable of detecting all known SARS-CoV-2 variants, essential for managing the ongoing pandemic in Europe.
BD (Becton, Dickinson and Company) has submitted a 510(k) premarket notification to the U.S. FDA for its BD Alaris™ System, a widely used infusion pump in U.S. hospitals. The submission aims to update regulatory clearance, implement new features, and address existing recall issues. The new software version will enhance clinical, operational, and cybersecurity aspects. BD emphasizes this submission as a pivotal step in their commitment to healthcare improvement. However, the FDA review process includes risks and there is no guarantee of clearance or specific timing.
BD (Becton, Dickinson and Company) has partnered with USA Track & Field (USATF) to implement rapid COVID-19 testing for athletes at the Journey to Gold events. Utilizing the BD Veritor™ Plus system, tests will be administered to ensure athlete safety as they prepare for the U.S. Olympic Trials. The testing program includes administering tests every two days, exceeding U.S. Olympic Committee guidelines. To date, 410 tests have been conducted with two positive results. This initiative aligns with BD's commitment to supporting safe return to competition and community health.
BD (Becton, Dickinson and Company) is voluntarily recalling specific lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator due to a manufacturing defect that can lead to broken glass and solution release. The recall affects products distributed in the United States and Puerto Rico. While no severe injuries have been reported, potential risks include superficial to deep lacerations and possible infection. BD has received 56 complaints, with one incident of laceration. The company is notifying affected customers and providing disposal instructions.
BD (Becton, Dickinson and Company) has announced a commitment of $1 million over five years to support UNICEF USA's initiatives targeting the elimination of Maternal and Neonatal Tetanus (MNT) in at-risk countries. This donation builds on BD's ongoing partnership, contributing over $10.8 million to UNICEF's efforts since 1997. The initiative aims to vaccinate women and promote safe childbirth practices, addressing a disease that claims a newborn every 21 minutes. BD continues to advocate for healthcare access among vulnerable populations.
Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
